Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

NCT02930265 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether the medication liraglutide can improve heart function in adults with ischemic cardiomyopathy.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 400 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2016-09 · est. completion 2018-03

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT02930265 ↗

Description as written by the study sponsor.

It has been known that liraglutide reduces infarct size, improved left ventricular function, reduce myocardial stunning, and play a protective role in myocardial ischemia-reperfusion injury for patients with acute myocardial infarction. But it is not sure whether liraglutide can benefit patients with ischemic cardiomyopathy. This study aim to explore the effect of Liraglutide in improving cardiac function for patients with ischemic cardiomyopathy.

Treatments tested

Liraglutide also known as Saxenda Drug

Liraglutide intervention group will accept liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)

Main thing measured	main adverse cardiovascular events
Sponsor	Chinese PLA General Hospital
Conditions studied	Ischemic Cardiomyopathy
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02930265 ↗